Print
Email
Exagamglogene autotemcel (exa-cel) is an investigational treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). On April 3, 2023, CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated revealed that they had successfully submitted their Biologics Licence Applications (BLAs) to the U.S. Food and Drug Administration (FDA). The BLAs also contained requests for Priority Review, which, if approved, would shorten the FDA's review period from 12 months to eight months starting from the time the application was submitted.
The EU and UK filings were completed in 2022 and were validated by EMA and MHRA, respectively. The regulatory review process began in January 2023.
This significant milestone in the field of medicine and biotechnology has the potential to offer a breakthrough treatment for SCD and TDT patients, reducing their pain and improving their quality of life. Exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy with the objective at generating high levels of foetal haemoglobin in red blood cells to help patients with SCD and those with TDT lessen or avoid painful and incapacitating vaso-occlusive crises (VOCs). Exa-cel has a promising future, as evidenced by earlier study results that were published in The New England Journal of Medicine in January 2021.
The news of the BLAs submission may cause a significant increase in CRISPR's stock, demonstrating the company's lead in a competitive area of medical research. If approved, exa-cel treatment from CRISPR and Vertex Pharmaceuticals would be the first U.S.-marketed therapy based on CRISPR, a Nobel-winning technology that rewrites faulty genes.
The approval of exa-cel would mark a significant advancement in the field of medicine and biotechnology and is a testament to the transformative nature of CRISPR technology, which has progressed rapidly since its discovery.
The field of CRISPR technology has made impressive strides in a short amount of time, progressing from the initial discovery of the CRISPR platform to the first regulatory submissions for a CRISPR-based medicine in less than a decade. This progress is a testament to the transformative potential of this revolutionary technology, which has captured the attention of scientists, medical professionals, and investors alike.
With the submission of regulatory filings for investigational treatments such as exa-cel, there is renewed hope for the millions of people around the world who suffer from debilitating genetic disorders. The rapid pace of development in the CRISPR field has set the stage for continued innovation and advancement in the years to come, providing the potential for further breakthroughs and transformative therapies for a range of genetic disorders.
SCD and TDT are debilitating genetic disorders that affect millions of people worldwide, causing severe pain, anemia, and other complications. The majority of current treatments are unsuccessful or have serious negative effects. If exa-cel is approved, it has the potential to significantly reduce patients' pain and improve their quality of life by correcting the genetic mutations that cause SCD and TDT. This could pave the way for other CRISPR-based therapies that could treat a range of genetic disorders, offering hope for millions of people worldwide.
Gene-editing advances like CRISPR have spawned dozens of start-ups in the past decade, including Intellia Therapeutics, Editas Medicine, Beam Therapeutics, Caribou Biosciences, and Prime Medicine. A number of these companies are also working on sickle-cell therapies, highlighting the potential for further innovation and competition in this field.
BioIntel360 suggests that the submission of the BLAs for exa-cel is a significant achievement for CRISPR Therapeutics and Vertex Pharmaceuticals and has the potential to offer hope for millions of patients suffering from SCD and TDT worldwide. The transformative nature of CRISPR technology is evident in this milestone, and if approved, exa-cel could pave the way for further CRISPR-based therapies to treat a range of genetic disorders.
